Improving Quality of Life in Neovascular Age-Related Macular Degeneration (nAMD): Evaluating New Dosing Options and Mechanisms for Delivery of Agents

A continuing medical education activity sponsored by NAMCP and AAMCN.

Reducing Treatment Burden and Improving Outcomes in Neovascular Age-Related Macular Degeneration (nAMD): What Managed Care Needs to Know about Emerging Therapies is a 3-part live webinar series that will provide attendees with the latest information in the management of nAMD

This is part 2 of the series focusing on dosing and mechanism of action of new agents

This activity is an archive from the webinar held November 15, 2019

This activity is valid from December 1, 2019 to December 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Novartis Pharmaceuticals Corporation

Age-related macular degeneration (AMD) is a leading cause of severe vision loss among people aged 50 years and older. It is estimated that nearly 3 million individuals in the US will develop AMD by 2020 and that the prevalence will continue to increase due to the aging population. Neovascular, or "wet" AMD imposes a high burden on patients, eye care providers and payers alike, as optimal visual outcomes have been contingent on regular, ongoing treatment. Fortunately for patients with nAMD, new treatments have arrived or are on the horizon. This webinar series will feature strategies to reduce treatment burden and improve outcomes as experts will discuss the current burden of treatment, evaluate new dosing and administration schedules, as well as review the safety and efficacy of therapies in late-stage development.

Upon completion of this activity, participants will be able to:

  • Assess challenges to patient adherence, dosing and quality of life in nAMD management

  • Examine dosing schedules for new and emerging therapies and how they could change patient management and treatment frequency

  • Analyze examine treatment durability associated with new and emerging agents in the management of nAMD

  • Discuss strategies to monitor and manage adverse events associated with emerging agents in nAMD in order to improve patient adherence and quality of life

  • Review evolving individualized treatment plans based on evidence-based monitoring strategies for patients with nAMD

Faculty: Michael A. Singer, MD
Director of Clinical Research
Medical Center Ophthalmology Associates
Clinical Professor
University of Texas Health Science Center


Dr. Singer serves as a consultant for Aerie, Allegro, Allergan, Genentech, Kodiak, Novartis, Regeneron, and Santen. He serves on the speaker’s bureau for Allergan, Genentech, Mallinckrodt, Novartis, Regeneron, and Spark. He has in the past received grant or research support from Aerie, Allegro, Allergan, DRCR, Genentech, Icon, Ionis, Kalvista, Kodiak, , Novartis, Opthea, Optos, Regeneron, Santen, Senju, and Sydnexis.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Novartis Pharmaceuticals Corporation

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue